Datapoint: Actemra Granted EUA for Use in COVID Patients

The FDA last week granted Roche’s Actemra an emergency use authorization to treat both adult and juvenile patients hospitalized with COVID-19. The arthritis drug was previously approved for compassionate use, but can now be administered to COVID patients who require oxygen support, in tandem with corticosteroids. For the treatment of rheumatoid arthritis, the intravenous form of Actemra holds covered or better status for 93% of all insured lives under the medical benefit.

SOURCE: MMIT Analytics, as of 6/28/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 16

Datapoint: AstraZeneca, Daiichi Score Earlier Breast Cancer Use for Enhertu

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 12

Datapoint: Pfizer Inks Biohaven Deal

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 11

Datapoint: Sentara to Open Community Care Centers, Launch New Model

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today